SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending due to intensifying acquisition speculation involving major tech titans, with community discourse fueled by leaked reports of Amazon buyout discussions and competing interests from SpaceX. Investors are actively debating the company's valuation, the strategic importance of its proprietary satellite spectrum, and the complex, multi-layered partnerships that make it a critical asset in the race for global direct-to-device connectivity.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant downward pressure as disappointing delivery figures for the first quarter highlight growing concerns over demand and inventory buildup. The community remains deeply divided, with bears pointing to slowing EV sales and fading brand sentiment, while bulls continue to pivot the narrative toward the company's long-term ambitions in AI, robotics, and the potential impact of a future SpaceX IPO.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing significant investor interest driven by strong fourth-quarter financial results, including substantial revenue growth and a strengthened balance sheet that has boosted confidence in its long-term turnaround strategy. The community is actively discussing potential catalysts such as the company's expansion into pharmaceutical manufacturing, participation in government-led reshoring initiatives, and ongoing speculation regarding its valuation as a specialized industrial and materials science player.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense market activity as it prepares to join the S&P 500, triggering massive, price-insensitive buying from passive index funds. The community is heavily divided between bulls highlighting the company's critical role in AI-driven optical infrastructure and skeptics who warn of extreme valuations and potential over-extension.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is facing downward pressure amid significant market volatility and high-profile security incidents within its ecosystem, leading to intense debate among community members about its long-term viability. While some investors view the current price action as a buying opportunity, others are actively rotating into alternative networks or stable ETFs due to concerns over network stability and crypto-market momentum.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh an upcoming earnings report against broader volatility in the cannabis sector, with community discussion intensely focused on potential federal rescheduling news and skepticism surrounding management's performance. While some participants are anticipating a positive breakout fueled by a turnaround strategy and analyst upgrades, others remain deeply critical of share dilution and the stock's long-term performance.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Investors in KELYB are intensely focused on a potential short squeeze fueled by an extremely low float of approximately 255,000 shares and significant insider accumulation, with many holding out for an earnings catalyst next week to trigger a rebound. Despite recent price volatility and concerns over manipulation, the community remains divided between those calling for patience for a parabolic run and others warning of a trap following a sharp pullback from recent highs.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant market interest following a major deal to regain full ownership of its Ireland-based Fab 34 facility, a move signaling long-term manufacturing confidence despite broader semiconductor sector volatility. The community is actively debating the company's aggressive capital strategy, weighing the potential for an earnings turnaround against ongoing concerns regarding market manipulation and macroeconomic pressures.

SBA Communications Corp. is a real estate investment trust, which engages in the provision of wireless communications infrastructures. It operates through the following business segments: Domestic Site Leasing, International Site Leasing, and Site Development. The Domestic Site Leasing segment includes AT&T, Sprint, T-Mobile, and Verizon Wireless. The International Site Leasing segment acquires and develops towers. The Site Development segment is involved in consulting and construction activities. The company was founded by Steven E. Bernstein in 1989 and is headquartered in Boca Raton, FL.

SBA Communications Corp - Ordinary Shares - Class A

SBA Communications is currently attracting attention due to circulating buyout rumors and ongoing speculation regarding potential consolidation in the wireless infrastructure sector. While investors remain focused on the company's long-term 5G tailwinds and site leasing durability, community discourse is heavily weighed by concerns over high debt levels and the impact of interest rates on future profitability.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is currently trending as investors speculate on its potential for a regulatory rebound following a previous FDA complete response letter (CRL) for its RP1 treatment in advanced melanoma. The community is heavily divided, with intense debate centered on the upcoming Type A meeting, the potential for an expedited path forward despite high hurdles, and significant high-risk activity in the options market as traders weigh the binary outcome of its long-term development plans.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock

Citigroup boosted their target price on shares of Biohaven from $14.00 to $17.00 and gave the company a "buy" rating in a report on Thursday...

Biohaven (NYSE:BHVN) Shares Up 10.5% - Here's Why

Biohaven (NYSE:BHVN) Stock Price Up 10.5% - Still a Buy...

Biohaven (NYSE:BHVN) Trading 6.2% Higher - Here's Why

Biohaven (NYSE:BHVN) Trading Up 6.2% - What's Next...

JPMorgan Chase & Co. Sells 1,236,587 Shares of Biohaven Ltd. $BHVN

JPMorgan Chase & Co. trimmed its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 48.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,335,455 shares of the company's stock after selling 1...

Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages

Biohaven Ltd. (NYSE:BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have is...

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel...

TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00

TD Cowen upped their price objective on Biohaven from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday...

<ul class="summary-bullets"><li>Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026.</li><li>CEO Ian Mortimer said that the trial results “exceeded expectations.”</li><li>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout.</li></ul><p><br>Xenon Pharmaceuticals Inc. (XENE) on Monday announced that it has commenced an underwritten public offering of $500 million of its common shares on the heels of the company announcing positive results from a trial of azetukalner in focal onset seizures (FOS).</p><p>The company said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to a placebo.</p><p>Shares of XENE closed 50% higher in the regular hours of trading.</p><h2 class="st-heading-2">Trial Data</h2><p>With the higher 25 mg dose, a 53.2% median percent change from baseline in monthly FOS frequency was observed, compared with 10.4% for the placebo, the company said.</p><p>Azetukalner also demonstrated a safety and tolerability profile consistent with prior studies, prompting the company to plan submitting a new drug application to the U.S. Food and Drug Administration (FDA) for the treatment of focal onset seizures in the third quarter of 2026.</p><p>CEO Ian Mortimer said that the trial results “exceeded expectations.”</p><p>“Epilepsy is one of the most common neurological diseases, and foundational antiseizure medications do not provide sufficient seizure control for up to 50% of patients, so we are very optimistic about the opportunity for azetukalner to meaningfully shift the epilepsy treatment paradigm,” said CMO Chris Kenney.</p><p>Focal onset seizures, or epilepsy, originate in one localized area of the brain, causing symptoms based on that specific region.</p><h2 class="st-heading-2">Wall Street Reaction</h2><p>Following the trial data announcement, several analysts hiked their price targets on the stock, while also reflecting on the news’ impact on the shares of Biohaven (<a href="https://stocktwits.com/symbol/BHVN">BHVN</a>), which is developing an investigational drug Opakalim for epilepsy, depression, and pain.</p><p>Jefferies raised the firm's price target on Xenon Pharmaceuticals to $100 from $65 and kept a ‘Buy’ rating on the shares. The firm said it thinks azetukalner has the attributes of a top-selling epilepsy pill, driven by best-in-class focal epilepsy data. In 2026, Xenon shares could grind higher as Big Pharma interest rises and as the Street gauges azetuklaner's peak sales potential, the analyst told investors in a research note.</p><p>RBC Capital raised the firm's price target on Xenon Pharmaceuticals to $80 from $59 and kept an ‘Outperform’ rating on the shares, citing a belief that today's "strong" azetukalner data further increases the likelihood that the drug will be approved. The firm, which now estimates 90% odds of success, also sees higher market uptake than previously anticipated and greater potential for the drug to be priced at a premium.</p><h2 class="st-heading-2">Biohaven Still Holds Chance</h2><p>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout. Azetukalner showed efficacy in-line with expectations, but with a meaningful safety disadvantage, giving opakalim room to differentiate, it said. The firm believes the results continue to highlight an opportunity for opakalim, or BHV-7000, which has shown meaningful evidence of efficacy with better safety and tolerability.</p><p>Raymond James expects Biohaven to present topline results from the first pivotal trial for opakalim, testing a 25 mg and 50 mg dose, in the second half of 2026, which will more concretely establish the target product profile.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around XENE stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/XENE">XENE stock</a> has gained 83% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vrtx-soars-in-extended-hours-after-experimental-drug-shows-positive-changes-in-autoimmune-kidney-disease/cZdVDGuRIed">VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.

Equity

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.


Biohaven (NYSE:BHVN) Shares Gap Up - Time to Buy?

Biohaven (NYSE:BHVN) Shares Gap Up - Here's Why...

TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN

TD Asset Management Inc lowered its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 53.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd